Skip to content
Sample Page
Author:
Benitec Biopharma Inc.
Posted Date:
May 14, 2026
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Benitec Biopharma Inc.
May 14, 2026
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Benitec Biopharma Inc.
April 28, 2026
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
Benitec Biopharma Inc.
March 10, 2026
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Benitec Biopharma Inc.
March 9, 2026
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
Benitec Biopharma Inc.
February 23, 2026
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
Benitec Biopharma Inc.
February 12, 2026
